assignment
Not Recruiting

Evaluation of Lenvatinib, MK-4830, Pembrolizumab, and Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma Naïve to PD-1/PD-L1 Treatment

Trial ID
2023-505188-36-00
Protocol
MK-3475-06A

Register record, history and transparency: CTIS.eu

Trial statistics

science
7
test molecules
location_city
11
research sites
public
4
countries
medical_information
1
disease
person_search
11
investigators
handshake
4
vendors

Diseases & Conditions

Oesophageal squamous cell carcinoma

Objectives

The primary objective of this study is to evaluate the **safety** and tolerability of combination treatments in participants with advanced esophageal squamous cell carcinoma (ESCC) that have not been previously evaluated in separate studies. Additionally, the study aims to estimate the objective response rate (ORR) as assessed by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). These objectives are clinically relevant as they provide critical insights into the potential therapeutic benefits and risks associated with novel treatment combinations, which is essential for advancing treatment options for ESCC.

Secondary objectives include: - Evaluating progression-free survival (PFS) as assessed by BICR per RECIST 1.1. - Evaluating the duration of response (DOR) as assessed by BICR per RECIST 1.1. - Evaluating overall survival (OS). - Evaluating the safety and tolerability of investigational treatment combinations based on the proportion of participants with adverse events (AEs).

Participants

The clinical trial involves a total of **71 participants** diagnosed with **advanced esophageal squamous cell carcinoma (ESCC)**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. Participants were selected based on specific criteria, including a histologically or cytologically confirmed diagnosis of metastatic or locally advanced unresectable ESCC, and documented disease progression on one prior line of standard therapy. The trial does not include a vulnerable population. Participants are required to have adequately controlled blood pressure, and any adverse events from previous anticancer therapies must have resolved to Grade 1 or baseline, except for certain conditions like endocrine-related adverse events that are managed with hormone replacement or Grade 2 neuropathy. Lifestyle factors such as diet and physical activity are not specified as part of the selection criteria for this trial.

Plans and Procedures

The clinical trial is designed to evaluate the safety and efficacy of investigational agents, with or without **pembrolizumab**, and/or chemotherapy in participants with advanced esophageal squamous cell carcinoma (ESCC) who are naïve to PD-1/PD-L1 treatment. This study follows a Phase 1/2 open-label, umbrella platform design. The trial is expected to commence on April 19, 2023, and conclude by September 21, 2026. Participants will be randomly assigned to different treatment arms, ensuring a controlled and unbiased assessment of the investigational therapies. The trial will be conducted in a double-blind manner to minimize bias and ensure the integrity of the results.

The sequence of study visits begins with an inclusion (screening) visit, where participants will be assessed for eligibility based on criteria such as a confirmed diagnosis of metastatic or locally advanced unresectable ESCC, prior disease progression on standard therapy, and the availability of a baseline tumor sample. Following the screening, participants will enter the safety lead-in phase, where the primary objective is to evaluate the safety and tolerability of the combination treatments. Subsequent follow-up visits will monitor the participants for dose-limiting toxicities, adverse events, and treatment discontinuations due to adverse events. The end-of-study visit will assess the objective response rate, progression-free survival, duration of response, and overall survival.

Participant involvement is expected to last until the end of the trial in 2026, with regular follow-up visits scheduled throughout the study duration. Conditions that may lead to early termination from the study include the occurrence of severe adverse events, non-compliance with study protocols, or withdrawal of consent by the participant. The trial aims to provide comprehensive data on the safety and efficacy of the investigational treatments, contributing valuable insights into the management of advanced ESCC.

Treatment

The clinical trial involves the administration of several investigational agents and standard-of-care therapies for participants with advanced esophageal cancer. **Lenvatinib** is one of the experimental medications used in this study. It is provided in the form of a capsule and is administered orally. The active substance, lenvatinib, is of chemical origin and is produced by Merck & Co. Inc. The specific dosage and frequency of administration are determined based on the study protocol and participant response.

Another investigational agent, **MK-4830**, is administered as a concentrate and solvent for concentrate for solution for infusion. This biological product is delivered via intravenous infusion. The active substance, MK-4830, is a protein-based compound also developed by Merck & Co. Inc. The dosing schedule is tailored to the study's requirements and participant tolerance.

**MK-4280A** is a solution for infusion containing the active substances pembrolizumab and favezelimab. This biological product is administered through intravenous infusion. Pembrolizumab is a well-known monoclonal antibody, and favezelimab is an anti-LAG3 monoclonal antibody. Both substances are of protein origin and are provided by Merck & Co. Inc. The administration schedule is aligned with the study's objectives and safety assessments.

**KEYTRUDA** (pembrolizumab) is another investigational agent used in the trial. It is provided as a 25 mg/mL concentrate for solution for infusion and is administered intravenously. Pembrolizumab is a protein-based monoclonal antibody developed by Merck Sharp & Dohme B.V. The dosing regimen is specified in the study protocol to ensure optimal therapeutic outcomes and participant safety.

In addition to the investigational agents, the study includes standard-of-care chemotherapy agents such as **Irinotecan Hydrochloride** and **Paclitaxel**. Both are chemical compounds administered via intravenous infusion. The pharmaceutical form for both agents is denoted as PHF00230MIG. The dosing and administration of these agents follow established clinical guidelines and are adjusted based on individual participant needs and responses.

Efficacy

Efficacy in this clinical trial will be assessed using several primary and secondary endpoints. The primary endpoints include the **Objective Response Rate (ORR)**, which will be evaluated by a blinded independent central review according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Additionally, the number of participants experiencing a dose-limiting toxicity (DLT), adverse events (AEs), and those who discontinue study treatment due to an AE during the safety lead-in phase will be recorded.

Secondary endpoints will focus on **Progression-Free Survival (PFS)**, **Duration of Response (DOR)**, and **Overall Survival (OS)**. The trial will also monitor the number of participants experiencing at least one adverse event and those who discontinue study treatment due to an AE during the efficacy phase. These efficacy parameters will be collected and analyzed at various timepoints throughout the study to provide a comprehensive evaluation of the investigational agents' impact on participants with advanced esophageal cancer.

Inclusion and Exclusion Criteria

check_circle

Inclusion Criteria

  • Histologically or cytologically confirmed diagnosis of metastatic or locally advanced unresectable ESCC.
  • Has experienced investigator documented radiographic or clinical disease progression on one prior line of standard therapy.
  • Has an evaluable baseline tumor sample (newly obtained or archival) for analysis.
  • Has adequately controlled blood pressure (BP) with or without antihypertensive medications.
  • Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy are eligible.
cancel

Exclusion Criteria

  • Direct invasion into adjacent organs such as the aorta or trachea.
  • Has experienced weight loss >10% over approximately 2 months prior to first dose of study therapy.
  • Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.
  • Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication.
  • Known additional malignancy that is progressing or has required active treatment within the past 3 years, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ that has undergone potentially curative therapy.
  • Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Active autoimmune disease that has required systemic treatment in past 2 years.
  • History of human immunodeficiency virus (HIV) infection.
  • History of Hepatitis B or known active Hepatitis C virus infection.
  • History of allogenic tissue/solid organ transplant.
  • Clinically significant cardiovascular disease within 12 months from first dose of study intervention.
  • Participants with known gastrointestinal (GI) malabsorption or any other condition that may affect the absorption of lenvatinib.
  • Has risk for significant GI bleeding.
  • Has had a serious nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to allocation/randomization.
  • Has significant bleeding disorders, vasculitis, or has had a significant bleeding episode from the GI tract within 12 weeks prior to allocation/randomization.

Trial Status by Country

Country Status Start of Recruitment Planned Patients
France FranceNot Recruiting19 Apr 20237
Germany GermanyNot Recruiting19 Apr 20235
Italy ItalyNot Recruiting19 Apr 20236
Norway NorwayNot Recruiting19 Apr 20232

Sites & Investigators

Investigational Products

Details about the medicinal products being studied in this clinical trial.

Product Name Role in Trial Formulation Administration Max Daily Dose Treatment Duration EU MP Number
KEYTRUDA 25 mg/mL concentrate for solution for infusion
TestCONCENTRATE FOR SOLUTION FOR INFUSIONINTRAVENOUS INFUSION——PRD4323105
Lenvatinib
TestCAPSULEORAL USE——PRD9414230
MK-4280A
TestSOLUTION FOR INFUSIONINTRAVENOUS INFUSION——PRD9364228
PACLITAXEL
TestPHF00230MIGINTRAVENOUS INFUSION——SCP129816
Lenvatinib
TestCAPSULEORAL USE——PRD9414231
MK-4830
TestCONCENTRATE AND SOLVENT FOR CONCENTRATE FOR SOLUTION FOR INFUSIONINTRAVENOUS INFUSION——PRD11040309
IRINOTECAN
TestPHF00230MIGINTRAVENOUS INFUSION——SCP105621456

Conditions Studied in This Trial

Interventions Studied in This Trial

vaccines
Irinotecan Hydrochloride
37 trials

Also investigated for

Colorectal cancer metastatic 8Colorectal cancer 4Pancreatic carcinoma 4Pancreatic carcinoma metastatic 4
vaccines
Lenvatinib
69 trials

Also investigated for

Hepatocellular carcinoma 20Renal cell carcinoma 9Endometrial cancer 6Malignant melanoma 5
vaccines
MK-4830
11 trials

Also investigated for

Non-small cell lung cancer 3Oesophageal squamous cell carcinoma 2Colorectal cancer stage IV 1Fallopian tube cancer 1
vaccines
Paclitaxel
271 trials

Also investigated for

Non-small cell lung cancer 49Ovarian cancer 20Breast cancer 19Triple negative breast cancer 18
vaccines
Pembrolizumab
477 trials

Also investigated for

Non-small cell lung cancer 88Malignant melanoma 39Non-small cell lung cancer metastatic 33Neoplasm 28
vaccines
Favezelimab
15 trials

Also investigated for

Haematological malignancy 2Malignant melanoma 2Neoplasm 2Renal cell carcinoma 2